The Ministry of Health of Russia has registered the medicinal product “Nefopam, solution for infusions and intramuscular administration 10 mg/mL”, the marketing authorisation owner is LLC Endocrine Technologies, and the manufacturer (all stages including release control) is FSUE Moscow Endocrine Plant.
Marketing authorisation No. LP-005871, registration date 22/10/2019.
The medicinal product “Nefopam” (INN - Nefopam) belongs to the pharmacotherapeutic group - analgetic of central action.
Nefopam structurally differs from other known painkillers, is non-narcotic analgetic of central action and can be used at stage II of “pain relief ladder” in the treatment of mild and moderate pain.
As per the effective guidance, the product is used for symptomatic treatment of the acute pain syndrome, including post-surgery pain in adults and children over the age of 15 years.
The advantages of Nefopam over opioid analgesics and non-steroidal anti-inflammatory products are:
- absence of the effect upon platelet aggregation and inhibitory action upon the central nervous system;
- positive effect in postsurgical shiver;
- absence of anti-inflammatory and antipyretic action;
- absence of respiratory depression and effect on intestinal motility;
The product was developed and registered as part of the partnership project FSUE Moscow Endocrine Plant and LLC Endocrine Technologies.
The Enterprise plans to release first product commercial batches by the end of 2019.
Comment type is not specified in the component properties.